A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma
PHASE1CompletedINTERVENTIONAL
Enrollment
24
Participants
Timeline
Start Date
July 31, 1991
Study Completion Date
April 30, 2001
Conditions
B Cell Lymphoma
Interventions
DRUG
IgG-RFB4-SMPT-dgA
Trial Locations (1)
20892
National Cancer Institute (NCI), Bethesda
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00001271 - A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma | Biotech Hunter | Biotech Hunter